Compare CRMT & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRMT | CTXR |
|---|---|---|
| Founded | 1981 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7M | 18.9M |
| IPO Year | 2026 | 2010 |
| Metric | CRMT | CTXR |
|---|---|---|
| Price | $2.13 | $0.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $29.50 | $6.00 |
| AVG Volume (30 Days) | ★ 946.4K | 426.4K |
| Earning Date | 06-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.36 | 43.38 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,390,932,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.92 | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.38 | $0.48 |
| 52 Week High | $62.55 | $2.24 |
| Indicator | CRMT | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 21.83 | 41.90 |
| Support Level | $1.38 | $0.48 |
| Resistance Level | $13.68 | $0.74 |
| Average True Range (ATR) | 1.49 | 0.04 |
| MACD | -0.43 | -0.00 |
| Stochastic Oscillator | 6.98 | 16.67 |
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.